Similar Papers

Paper Title
Journal
Date
Author
Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
Peter Hillmen ...
Blood | VOL. 136
Peter Hillmen, et. al.Peter Hillmen ...
05 Nov 2020
Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)
Dr Brian Koffman ... John M Pagel
Blood | VOL. 138
Dr Brian Koffman, et. al.Dr Brian Koffman ... John M Pagel
05 Nov 2021
Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Maximilian Stahl ...
Blood | VOL. 136
Maximilian Stahl, et. al.Maximilian Stahl ...
05 Nov 2020
CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial
Gail J Roboz ... Gert Ossenkoppele
Blood | VOL. 136
Gail J Roboz, et. al.Gail J Roboz ... Gert Ossenkoppele
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde ... Margaret Kasner
Blood | VOL. 145
Lindsay Wilde, et. al.Lindsay Wilde ... Margaret Kasner
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.